Inventor · disambiguated record
Benjamin Rossi
Also filed as: ROSSI BENJAMIN
20 granted patents·23 pending applications·96 citations·filing 2009–2025
94Inventor score
Top patents by PatentIndex Score
43 records- 0195US11891444B2Variable regions for NKp46 binding proteinsINNATE PHARMA·Filed 2021·Granted Feb 6, 2024·3 cites·15 claims
- 0294US11267897B2Multispecific NK engager proteinINNATE PHARMA·Filed 2018·Granted Mar 8, 2022·8 cites·19 claims
- 0394US10577419B2KIR3DL2 binding agentsINNATE PHARMA·Filed 2015·Granted Mar 3, 2020·15 cites·10 claims
- 0493US10113003B2Multispecific NK engager proteinsINNATE PHARMA·Filed 2016·Granted Oct 30, 2018·15 cites·28 claims
- 0589US11377503B2Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptideINNATE PHARMA·Filed 2019·Granted Jul 5, 2022·3 cites·13 claims
- 0689US10246510B2KIR3DL2 binding agentsINNATE PHARMA·Filed 2013·Granted Apr 2, 2019·9 cites·20 claims
- 0788US11858990B2KIR3DL2 binding agentsINNATE PHARMA·Filed 2020·Granted Jan 2, 2024·2 cites·7 claims
- 0888US11001629B2Variable regions for NKp46 binding proteinsINNATE PHARMA·Filed 2016·Granted May 11, 2021·7 cites·6 claims
- 0988US9828427B2Anti-KIR3D antibodiesINNATE PHARMA·Filed 2015·Granted Nov 28, 2017·9 cites·7 claims
- 1087US11078274B2Siglec neutralizing antibodiesINNATE PHARMA·Filed 2017·Granted Aug 3, 2021·3 cites·23 claims
- 1186US10519234B2NKp46 binding proteinsINNATE PHARMA·Filed 2015·Granted Dec 31, 2019·6 cites·12 claims
- 1285US11208480B2Multispecific antigen binding proteinsINNATE PHARMA·Filed 2015·Granted Dec 28, 2021·3 cites·8 claims
- 1380US11845795B2NKp46 binding proteinsINNATE PHARMA·Filed 2019·Granted Dec 19, 2023·1 cites·12 claims
- 1480US9181341B2Anti-KIR3D antibodiesANFOSSI NICOLAS·Filed 2010·Granted Nov 10, 2015·9 cites·11 claims
- 1580US2024124579A1Kir3dl2 binding agentsINNATE PHARMA·Filed 2023·Application pending·0 cites
- 1679US12202907B2Nucleic acids encoding and methods of producing proteins comprising antibody chainsINNATE PHARMA·Filed 2022·Granted Jan 21, 2025·0 cites·36 claims
- 1779US2024174748A1Variable regions for nkp46 binding proteinsINNATE PHARMA·Filed 2024·Application pending·0 cites
- 1878US11623954B2Siglec-9-neutralizing antibodiesINNATE PHARMA·Filed 2018·Granted Apr 11, 2023·1 cites·12 claims
- 1978US2024141042A1MULTISPECIFIC NKp46 BINDING PROTEINSINNATE PHARMA·Filed 2023·Application pending·0 cites
- 2077US11578136B2Compositions and methods for treating cancerINNATE PHARMA·Filed 2018·Granted Feb 14, 2023·1 cites·12 claims
- 2173US2023340143A1Compositions and methods for treating cancerINNATE PHARMA·Filed 2023·Application pending·0 cites
- 2272US11083785B2Siglec-10 antibodiesINNATE PHARMA·Filed 2016·Granted Aug 10, 2021·1 cites·9 claims
- 2371US2025236678A1Compositions and methods for treating cancerINNATE PHARMA·Filed 2025·Application pending·0 cites
- 2471US2025215107A1Multispecific nk engager proteinINNATE PHARMA·Filed 2025·Application pending·0 cites
- 2570US2023099801A1Restoration of t cell activity via the cd39/cd73 axisINNATE PHARMA·Filed 2022·Application pending·0 cites
- 2669US2023085847A1Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancerINNATE PHARMA·Filed 2022·Application pending·0 cites
- 2768US2021363249A1Siglec neutralizing antibodiesINNATE PHARMA·Filed 2021·Application pending·0 cites
- 2867US12252543B2Multispecific NK engager proteinINNATE PHARMA·Filed 2018·Granted Mar 18, 2025·0 cites·26 claims
- 2966US2022135676A1Multispecific antigen binding proteinsINNATE PHARMA·Filed 2021·Application pending·0 cites
- 3060US2025002601A1Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2INNATE PHARMA·Filed 2022·Application pending·0 cites
- 3159US2025297004A1Nectin-4 binding agentsINNATE PHARMA·Filed 2023·Application pending·0 cites
- 3257US2022025056A1Leucocyte immunoglobulin-like receptor neutralizing antibodiesINNATE PHARMA·Filed 2019·Application pending·0 cites
- 3357US2022025045A1Compounds and methods for treatment of head and neck cancerINNATE PHARMA·Filed 2019·Application pending·0 cites
- 3456US11447545B2Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancerINNATE PHARMA·Filed 2018·Granted Sep 20, 2022·0 cites·14 claims
- 3551US2024117042A1Immunohistochemistry methods and kir3dl2-specific reagentsINNATE PHARMA·Filed 2022·Application pending·0 cites
- 3650US2024294634A1Treatment of cancer with ilt-2 inhibitorsINNATE PHARMA·Filed 2020·Application pending·0 cites
- 3749US2019218308A1Restoration of t cell activity via the cd39/cd73 axisINNATE PHARMA·Filed 2019·Application pending·0 cites
- 3848US2024325557A1Treatment of cancerINNATE PHARMA·Filed 2021·Application pending·0 cites
- 3947US2010124555A1Compositions and Methods for Treating Pancreatic TumorsUNIV AIX MARSEILLE II·Filed 2009·Application pending·0 cites
- 4045US2019218304A1Potentiating the effect of atp releaseINNATE PHARMA·Filed 2019·Application pending·0 cites
- 4138US2020048345A1Multispecific antigen binding proteinsINNATE PHARMA·Filed 2016·Application pending·0 cites
- 4237US2014065154A1Tlr3 binding agentsGAUTHIER LAURENT·Filed 2012·Application pending·0 cites
- 4337US2017306014A1Cross reactive siglec antibodiesINNATE PHARMA·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Benjamin Rossi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →